Skip to main content

Table 3 Changes from baseline to 6-month visit in SGLT2 patients

From: Effect of sodium-glucose cotransporter 2 (SGLT2) inhibitors on left ventricular remodelling and longitudinal strain: a prospective observational study

  Baseline 6-month Δ from baseline p
Indexed LVM (g/m2) 98.5 ± 27.9 87.6 ± 18.4 − 10.8 ± 3.3 0.003
LV end-diastolic volume (ml) 103.3 ± 40.0 100.8 ± 34.0 − 2.5 ± 5.0 0.62
LV end-diastolic diameter (mm) 46.9 ± 5.0 45.7 ± 4.3 − 1.2 ± 0.67 0.09
LV ejection fraction (%) 62.9 ± 8.2 62.6 ± 8.4 − 0.4 ± 1.5 0.81
RWT 0.47 ± 0.07 0.46 ± 0.06 − 0.01 ± 0.01 0.44
GLS − 17.8 ± 2.9 − 19.1 ± 3.1 1.29 ± 0.47 0.01
LA indexed volume (ml/m2) 31.9 ± 9.8 31.2 ± 9.9 − 0.75 ± 1.28 0.56
E/A ratio 0.81 ± 0.39 0.92 ± 0.52 0.10 ± 0.05 0.07
Lateral e’ (cm/s) 8.31 ± 2.19 9.07 ± 2.57 0.76 ± 0.47 0.12
Septal e’ (cm/s) 5.91 ± 1.37 6.57 ± 1.60 0.66 ± 0.25 0.01
E/e’ ratio 10.5 ± 3.6 10.0 ± 3.9 − 0.52 ± 0.53 0.34
  1. LVM left ventricular mass, LV left ventricular, RWT relative wall thickness, GLS global longitudinal strain, LA left atrial